Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Yu-Fan Zhang, Jia-Jie Xie, Qi Wu, Xiao-Yu Zhou, Chen Zeng, Yan Zeng, Yi-Meng He, Man Guo, Fang-Yuan Teng, Yong Xu · 2026

Read Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials by Yu-Fan Zhang, Jia-Jie Xie, Qi Wu, Xiao-Yu Zhou, Chen Zeng, Yan Zeng, Yi-Meng He, Man Guo, Fang-Yuan Teng, Yong Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13541834.txt.

Description

Whether a popular class of diabetes drugs raises gut cancer risk is tested by Zhang and co-authors in a 2026 review. The drugs lower blood sugar by pushing sugar out in urine. Past reports on cancer risk conflict, so the team pooled results from randomized trials in type 2 diabetes.

Forty-eight trials with nearly fifty thousand patients were combined. Gut cancers were drawn from papers, extra files, and trial registries, since most trials logged them as side effects, not main outcomes. Two reviewers screened and scored each trial on their own. The pooled result gives patients and doctors a firmer read on a feared risk, within the limits of side-effect data.

Catalog record

CREATORYu-Fan Zhang, Jia-Jie Xie, Qi Wu, Xiao-Yu Zhou, Chen Zeng, Yan Zeng, Yi-Meng He, Man Guo, Fang-Yuan Teng, Yong Xu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13541834

Browse the full library · About the Tower of Babel